Bestatin Treatment and the Peripheral Lymphocyte Population in Cancer Patients
Bestatin, a substance produced by Streptomyces olivoreticuli, inhibits certain cell-membrane-associated enzymes and has been shown to augment immune responses in experimental animals. We have determined whether bestatin medication changed the peripheral lymphocyte population in 15 advanced cancer patients. After 2 weeks of daily, 30 mg oral bestatin medication, the lymphocyte counts remained essentially unchanged, but the frequency of E-rosette-forming lymphocytes increased. In vitro stimulation of the lymphocytes with PHA or PPD remained essentially unchanged while the natural-killer activity of the lymphocyte population increased in most patients. Bestatin treatment caused no detectable side effects.
KeywordsPurify Protein Derivative Leucine Aminopeptidase Chang Liver Cell Human Leukocyte Interferon Cytotoxic Index
Unable to display preview. Download preview PDF.
- 9.Suda H, Takita T, Aoyagi T, Umezawa H (1976) The structure of bestatin. J Antibiot (Tokyo) 29:100–101Google Scholar
- 10.Trinchieri G, Santoli D (1978) Antiviral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells. Enhancement of human natural killer cell activity by interferon and antagonistic inhibition of susceptibility of target cells to lysis. J Exp Med 147:1314–1333PubMedCrossRefGoogle Scholar
- 11.Umezawa H (1977) Recent advances in bioactive microbial secondary metabolites. J Antibiot (Tokyo) 30:138–163Google Scholar
- 12.Umezawa H, Aoyagi T, Suda H, Hamada M, Takeuchi T (1976) Bestatin, an inhibitor of aminopeptidase B produced by actinomycetes. J Antibiot (Tokyo) 29:97–99Google Scholar
- 13.Umezawa H, Ishizuka M, Aoyagi T, Takeuchi T (1976) Enhancement of delayed-type hypersensitivity by bestatin, an inhibitor of aminopeptidase B and leucine aminopeptidase. J Antibiot (Tokyo) 29:857–859Google Scholar